Tesamorelin vs sermorelin:
full 44-amino-acid vs truncated 29-amino-acid GHRH.

The central difference between tesamorelin and sermorelin is the length of the peptide chain. Human GHRH is a 44-amino-acid peptide — specifically, the full functional sequence is GHRH(1-44). Tesamorelin preserves this entire sequence with one modification: a trans-3-hexenoyl group attached to the tyrosine residue at the N-terminus (Tyr1). This hexenoyl modification blocks the peptide cleavage site that dipeptidyl peptidase-IV (DPP-IV) uses to rapidly degrade native GHRH in plasma, giving tesamorelin a meaningfully longer functional half-life.

Sermorelin, by contrast, is a truncated fragment of GHRH containing only the first 29 amino acids — GHRH(1-29). Early GHRH research established that the first 29 residues carry most of the receptor-binding activity, so a shorter peptide is biologically active. But sermorelin has no enzymatic protection at the N-terminus. DPP-IV cleaves sermorelin in plasma at the same rate it cleaves native GHRH, which is to say quickly. Sermorelin's functional half-life is roughly 10–20 minutes after subcutaneous injection, compared to 26–38 minutes for tesamorelin.

Both peptides bind the same GHRH receptor on pituitary somatotroph cells, and both trigger the same downstream cAMP cascade that releases growth hormone. Mechanistically, tesamorelin vs sermorelin is a comparison of potency and duration, not of pathway. The receptor response is identical — what differs is how much of each peptide reaches the receptor and for how long.

The pharmacokinetic difference between tesamorelin and sermorelin translates directly into clinical dosing and efficacy differences. A 2 mg dose of tesamorelin produces a discrete GH pulse of a magnitude that has been repeatedly validated in Phase III trials — typically peak GH of 15–40 ng/mL, returning to baseline within 2–4 hours. A comparable GH pulse from sermorelin requires a larger absolute dose, typically in the range of 0.2–0.5 mg for a therapeutic pulse and with a shorter-lasting IGF-1 response because the sermorelin half-life is shorter.

This is why sermorelin dosing protocols typically involve once-daily or more frequently — the shorter half-life means a single daily dose produces a smaller cumulative GH stimulation over 24 hours. Some sermorelin protocols use nightly dosing specifically to align the short GH pulse with the natural nocturnal GH peak and maximize cumulative GH exposure during sleep.

Tesamorelin's longer half-life produces a larger, more sustained GH pulse from a single injection. In head-to-head research contexts, patients on 2 mg tesamorelin daily show higher mean IGF-1 levels and more measurable visceral fat reduction than patients on sermorelin at typical clinical doses. This potency gap is why tesamorelin became the drug of choice for indications requiring substantial GHRH-mediated effect — like visceral fat reduction in HIV lipodystrophy — while sermorelin has remained more associated with general anti-aging and GH-support protocols where a milder, physiologic nudge is sufficient.

Tesamorelin has substantial Phase III clinical trial data supporting its efficacy. The Falutz trials (NEJM 2007 and 2010) established 15–20% visceral fat reduction over 26–52 weeks. The Stanley JAMA 2014 study showed 32% liver fat reduction in NAFLD patients over 12 months. These are randomized, placebo-controlled, MRI- or imaging-based endpoints, published in top-tier medical journals. Tesamorelin's efficacy claims rest on this tier-one clinical evidence.

Sermorelin's clinical data is sparser. Sermorelin was FDA-approved in the 1990s for growth hormone deficiency in children, but that pharmaceutical formulation was discontinued from the U.S. market in 2008 for commercial reasons rather than safety or efficacy concerns. Current sermorelin use is predominantly through compounding pharmacies for adult off-label use — anti-aging, body composition, general GH support — and is not supported by the same tier of modern clinical trial evidence as tesamorelin.

This doesn't mean sermorelin doesn't work. The mechanism is the same as tesamorelin, and smaller studies and clinical experience support benefits on IGF-1 levels, sleep quality, and modest body composition changes. But the magnitude of effect on visceral fat — the specific outcome where tesamorelin has proven dominance — is generally smaller with sermorelin. For patients whose primary goal is visceral fat reduction, the tesamorelin evidence base is stronger.

Tesamorelin is FDA-approved as a prescription drug for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is manufactured under full pharmaceutical GMP standards, reviewed by the FDA for safety, purity, and efficacy, and distributed through licensed pharmacies on prescription.

Sermorelin occupies a different regulatory category. The original FDA-approved sermorelin pharmaceutical product was withdrawn from the U.S. market in 2008, and since then sermorelin has been available primarily through compounding pharmacies under the framework that allows compounding of non-available drugs for individual patient prescriptions. This means sermorelin is still available with a prescription from a licensed provider — often through telehealth peptide therapy clinics — but it is not an FDA-approved drug in the same sense as tesamorelin. The compounded product undergoes less rigorous oversight, and quality can vary between compounding pharmacies.

Research-grade tesamorelin and sermorelin are both available through research peptide suppliers for laboratory use only. Neither has been reviewed by the FDA for purity or safety when used outside the pharmaceutical supply chain, and research-grade products are not intended for human consumption. This sourcing tier is outside the scope of both pharmaceutical and compounded use.

Both tesamorelin and sermorelin produce the same general category of side effects — injection site reactions, mild joint aching, occasional peripheral edema, headaches — because both elevate GH and IGF-1 through the same mechanism. The difference is magnitude: because tesamorelin produces a larger GH pulse, it tends to produce these effects more frequently and at higher intensity than sermorelin at typical clinical doses.

The most common tesamorelin side effects (injection site reactions in 20–30%, arthralgia in 13%, peripheral edema in 8–10%) are correspondingly less common with sermorelin — injection site reactions still occur but less frequently, and joint aching is rare except at higher sermorelin doses. The glucose tolerance concern that applies to tesamorelin applies to sermorelin as well but is typically less pronounced.

This milder side effect profile is one reason sermorelin is sometimes preferred for patients who are sensitive to the effects of elevated GH/IGF-1 or who are starting peptide therapy for the first time and want a gentler introduction. Patients on sermorelin who find the effects inadequate sometimes titrate up to tesamorelin for greater magnitude of benefit, accepting the corresponding increase in side effect frequency. See the tesamorelin side effects guide for the complete safety profile.

The choice between tesamorelin and sermorelin depends on the specific goal, tolerability, cost, and access considerations. The compounds are complementary rather than strictly competitive — they can serve different roles in peptide protocols.

Choose tesamorelin if: primary goal is visceral fat reduction, NAFLD or fatty liver is present, significant body composition change is the target, the stronger clinical evidence base matters for decision confidence, FDA-approved supply is accessible, and cost is not the primary constraint. Tesamorelin is the correct choice when the magnitude of GHRH stimulation needs to be large enough to produce the Phase III–validated effect on visceral adiposity.

Choose sermorelin if: primary goal is general GH support or anti-aging rather than targeted visceral fat reduction, tolerability to higher-magnitude GH effects is a concern, cost matters significantly (sermorelin is substantially cheaper), a gentler introduction to GHRH therapy is preferred, or the overall protocol intensity is intentionally mild. Sermorelin is a reasonable first step for patients who want to assess response to GHRH agonism before committing to tesamorelin dosing, costs, and intensity.

Use both sequentially: a common protocol pattern is 26 weeks of tesamorelin to produce the primary VAT reduction and body composition change, followed by transition to sermorelin for long-term maintenance. This approach captures the tesamorelin efficacy advantage during the intervention phase while downshifting to the more tolerable and less expensive sermorelin for ongoing support. This is not the only valid approach and clinical judgment varies.

Consider ipamorelin stack: both tesamorelin and sermorelin are frequently stacked with ipamorelin, a ghrelin receptor agonist that triggers GH release through a complementary pathway. The dual-pathway stack produces greater GH pulse amplitude than either peptide alone. Tesamorelin + ipamorelin is the higher-intensity version of this stack; sermorelin + ipamorelin is the milder version. For a direct comparison of tesamorelin vs ipamorelin as monotherapy, see the tesamorelin vs ipamorelin guide.